Expression of CD52 in peripheral T-cell lymphoma

被引：49
作者：
Piccaluga, Pier Paolo [1 ]
Agostinelli, Claudio [1 ]
Righi, Simona [1 ]
Zinzani, Pier Luigi [1 ]
Pileri, Stefano A. [1 ]
机构：
[1] Univ Bologna, Inst Hematol & Med Oncol L&A Seragnoli, S Orsola Malpighi Hosp, I-40138 Bologna, Italy
来源：
HAEMATOLOGICA | 2007年 / 92卷 / 04期
关键词：
T-cell lymphoma; CD52; expression;
D O I：
10.3324/haematol.10767
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis. We studied CD52 expression in 97 PTCL/U cases by immunohistochemistry on tissue-microarrays. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was available. We found that CD52 is expressed in approximately 40% of PTCLs/U at the same level as in normal T-lymphocytes. Although other factors may play a role in the in vivo response to alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher probability of treatment response.
引用
收藏
页码：566 / 567
页数：2
相关论文
共 11 条
  • [1] The role of alemtuzumab in the management of T-cell malignancies
    Dearden, Claire
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (02) : S44 - S52
  • [2] A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    Enblad, G
    Hagberg, H
    Erlanson, M
    Lundin, J
    MacDonald, AP
    Repp, R
    Schetelig, J
    Seipelt, G
    Österborg, A
    [J]. BLOOD, 2004, 103 (08) : 2920 - 2924
  • [3] Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
    Gallamini, A
    Stelitano, C
    Calvi, R
    Bellei, M
    Mattei, D
    Vitolo, U
    Morabito, F
    Martelli, M
    Brusamolino, E
    Iannitto, E
    Zaja, F
    Cortelazzo, S
    Rigacci, L
    Devizzi, L
    Todeschini, G
    Santini, G
    Brugiatelli, M
    Federico, M
    [J]. BLOOD, 2004, 103 (07) : 2474 - 2479
  • [4] GILLEECE MH, 1993, BLOOD, V82, P807
  • [5] Jaffe ES, 2001, TUMOURS HAEMATOPOIET, P191
  • [6] Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma:: a nation-wide survey
    Jantunen, E
    Wiklund, T
    Juvonen, E
    Putkonen, M
    Lehtinen, T
    Kuittinen, O
    Franssila, K
    Söderström, KO
    Leppä, S
    Elonen, E
    Remes, K
    Nousiainen, T
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 (04) : 405 - 410
  • [7] Piccaluga PP, 2007, J CLIN INVEST, V15
  • [8] Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
    Rai, KR
    Freter, CE
    Mercier, RJ
    Cooper, MR
    Mitchell, BS
    Stadtmauer, EA
    Santábarbara, P
    Wacker, B
    Brettman, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3891 - 3897
  • [9] Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
    Rodig, Scott J.
    Abramson, Jeremy S.
    Pinkus, Geraldine S.
    Treon, Steven P.
    Dorfman, David M.
    Dong, Henry Y.
    Shipp, Margaret A.
    Kutok, Jeffery L.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (23) : 7174 - 7179
  • [10] IMMUNOHISTOCHEMICAL ANALYSIS OF CDW52 ANTIGEN EXPRESSION IN NON-HODGKINS-LYMPHOMAS
    SALISBURY, JR
    RAPSON, NT
    CODD, JD
    ROGERS, MV
    NETHERSELL, ABW
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1994, 47 (04) : 313 - 317
12